Results 141 to 150 of about 37,077 (282)

EMB‐01, a Tetravalent Bispecific Antibody, Inducing Co‐Degradation of EGFR and c‐Met for Enhanced Anti‐Tumor Efficacy

Cancer Science, EarlyView.
As the breakthrough bispecific antibody targeting EGFR and c‐Met, EMB‐01 drives potent anti‐tumor efficacy by co‐degradation of both receptors. ABSTRACT The bispecific antibody EMB‐01 (bafisontamab), constructed using EpimAb's proprietary FIT‐Ig platform, is designed to simultaneously target epidermal growth factor receptor (EGFR) and receptor tyrosine
Jing Gao, Xi Jiao, Fang Ren, Xuan Wu, Jingyun Tan, Yuezong Bai, Yan Dai, Lixia Shen, Chengbin Wu, Lin Shen   +9 more
wiley   +1 more source

Identification and engineering of potent bispecific antibodies that protect against herpes simplex virus recurrent disease

Cell Reports
Summary: Herpes simplex virus (HSV) causes lifelong infections, including oral and genital herpes. There is no vaccine, and current antivirals are only partially effective at reducing symptoms and transmission.
Chingwei V. Lee, Hector Viadiu, Apurva Kalamkar, David I. Bernstein, Andrew Pae, Xinchao Yu, Sylvia Wong, Fernando J. Bravo, Sheng Ding, Elbert Seto, Magdeleine Hung, Yu Yu, Weimei Xing, Giuseppe A. Papalia, Wei Kan, Brian Carr, Majlinda Thomas, Leah Tong, Priyanka Desai, Nadine Jarrousse, Alexandre Mercier, Meghan M. Holdorf, Simon P. Fletcher, Emma Abernathy   +23 more
doaj   +1 more source

Tafasitamab as Monotherapy or in Combination in Japanese Patients With B‐Cell Non‐Hodgkin Lymphoma: Results From the Phase 1b J‐MIND Study

Cancer Science, EarlyView.
J‐MIND evaluated the safety and tolerability of tafasitamab, a CD19‐targeting monoclonal antibody, alone or in combination with other therapies in Japanese patients with B‐cell non‐Hodgkin lymphoma (NHL). Most common treatment‐emergent adverse events across all groups were hematological, and no serious tafasitamab treatment‐related or fatal adverse ...
Koji Izutsu, Noriko Fukuhara, Junichiro Yuda, Youko Suehiro, Shigeru Kusumoto, Marie‐Laure Casadebaig, Kazumi Suzukawa, Kentaro Fukushima   +7 more
wiley   +1 more source

New bispecific antibodies in diffuse large B-cell lymphoma

Haematologica
The CD20xCD3 T-cell-engaging bispecific antibodies are a highly active new treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Adrian G. Minson, Michael J. Dickinson
doaj   +1 more source

Cancer‐Specific Antihuman Podoplanin Antibody chLpMab‐2f Exerts Antitumor Effects Against Pleural Mesothelioma

Cancer Science, EarlyView.
Cancer‐specific antihuman podoplanin antibody chLpMab‐2f exerted antibody‐dependent cellular cytotoxicity and complement‐dependent cytotoxicity against pleural mesothelioma (PM) cell lines. Additionally, chLpMab‐2f inhibited tumor progression in mice with subcutaneously and intrathoracically transplanted human PM cells.
Aito Yoshida, Shinji Abe, Toshihiro Izumi, Satoshi Itakura, Keichiro Yamada, Takuya Wada, Takaaki Yamamoto, Chiemi Sato, Atsushi Mitsuhashi, Hirokazu Ogino, Seidai Sato, Tsutomu Shinohara, Masaki Hanibuchi, Mika K. Kaneko, Yukinari Kato, Yasuhiko Nishioka   +15 more
wiley   +1 more source

Impact of Sequential Ramucirumab Plus Docetaxel After PD‐1 Inhibitors on Anti‐PD‐1 Antibody‐Bound T‐Cell Dynamics and Clinical Outcomes

Cancer Science, EarlyView.
Ramucirumab (RAM) plus docetaxel (DOC) after PD‐1 inhibitors showed clinical activity, with responders exhibiting maintained anti–PD‐1 (IgG4+)‐bound CD8+ T cells and decreased IgG4+ Tregs. A sequential strategy of administering RAM plus DOC during persistent anti–PD‐1 antibody binding may be beneficial in patients with advanced non‐small cell lung ...
Kinnosuke Matsumoto, Yujiro Naito, Takayuki Shiroyama, Motohiro Tamiya, Kazumi Nishino, Akihiro Tamiya, Kyoichi Okishio, Yuhei Kinehara, Tomoki Kuge, Masahide Mori, Shingo Satoh, Hidekazu Suzuki, Satoshi Tetsumoto, Toshie Niki, Yasuhiko Suga, Akio Osa, Toshiyuki Minami, Shohei Koyama, Yoshito Takeda, Nobuyuki Takakura, Atsushi Kumanogoh   +20 more
wiley   +1 more source

Large scale controlled Fab exchange GMP process to prepare bispecific antibodies

Frontiers in Bioengineering and Biotechnology
Objective: Bispecific antibodies (BsAbs) have demonstrated significant therapeutic impacts for the treatment of a broad spectrum of diseases that include oncology, auto-immune, and infectious diseases.
Xia Yao, Mingquan Xie, Yinyin Ben, Yixiang Zhu, Gaoqiang Yang, Simon Chi Wai Kwong, Zhengliang Zhang, Mark L. Chiu, Mark L. Chiu   +8 more
doaj   +1 more source

AllergoOncology in Review: Harnessing Allergy in the Field of Oncology to Improve Patient Outcomes

Clinical &Experimental Allergy, EarlyView.
ABSTRACT The AllergoOncology field brings together the study of allergic and cancer immune responses, having evolved from early epidemiological studies that reported inverse associations between allergies, IgE and cancer risk. Insights from studying allergic inflammation are revealing previously unappreciated immune mechanisms that confer protective ...
Jakub Zydron, Anishaa Balaji, Jitesh Chauhan, Jack Alder, Xinyi Chen, Anna M. F. Wiegman, Aurelie Poli, Joanna Jacków‐Malinowska, Jack Cheeseman, Daniel I. R. Spencer, James McDonnell, James Spicer, Alexandra J. McCraw, Sophia N. Karagiannis   +13 more
wiley   +1 more source

Bispecific Dual‐Immune Checkpoint Inhibitor Associated Cutaneous Toxicity: A Report of Lorigerlimab Adverse Skin Reaction in Two Cancer Patients

Journal of Cutaneous Pathology, EarlyView.
ABSTRACT Lorigerlimab is a dual bispecific antibody (BsAb) targeting cytotoxic T‐lymphocyte‐associated protein 4 and programmed cell death protein 1 that is used for treatment of advanced solid cancers such as metastatic castration‐resistant prostate carcinoma.
Niloofar Sina, Fiorinda Muhaj, Volha Lenskaya, Doina Ivan, Victor G. Prieto, Jonathan L. Curry   +5 more
wiley   +1 more source

Factors Affecting Immune Reconstitution Post‐Allogeneic HSCT in Children: The Case for an Individualized Approach to Vaccination

European Journal of Haematology, EarlyView.
ABSTRACT Allogeneic hematopoietic stem cell transplantation (HSCT) is increasingly used to treat malignant and non‐malignant diseases. Following allogeneic HSCT, patients are particularly vulnerable to vaccine‐preventable diseases (VPD) because conditioning depletes immune cells, including memory cells.
Hélène Buvelot, Frederic Baleydier, Laure Pittet, Geraldine Blanchard‐Rohner   +3 more
wiley   +1 more source